Stockreport

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug [Seeking Alpha]

Exscientia Plc - American Depositary Shares  (EXAI) 
PDF The trial targeting a neurocondition called cerebral cavernous malformation (CCM) met the primary endpoint of safety and tolerability after 12 months of therapy, Recurs [Read more]